Allspring Global Investments Holdings LLC Sells 860 Shares of Intellia Therapeutics, Inc. $NTLA

Allspring Global Investments Holdings LLC decreased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 5.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,938 shares of the company’s stock after selling 860 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Intellia Therapeutics were worth $157,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. ARK Investment Management LLC increased its position in Intellia Therapeutics by 3.8% during the first quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company’s stock valued at $92,508,000 after acquiring an additional 474,629 shares during the last quarter. Vanguard Group Inc. increased its position in Intellia Therapeutics by 5.5% during the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company’s stock valued at $76,447,000 after acquiring an additional 561,978 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after purchasing an additional 38,521 shares during the last quarter. Jump Financial LLC grew its holdings in shares of Intellia Therapeutics by 38.9% in the first quarter. Jump Financial LLC now owns 503,809 shares of the company’s stock worth $3,582,000 after purchasing an additional 141,172 shares during the last quarter. Finally, Granahan Investment Management LLC grew its holdings in shares of Intellia Therapeutics by 55.3% in the first quarter. Granahan Investment Management LLC now owns 475,946 shares of the company’s stock worth $3,384,000 after purchasing an additional 169,436 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Insiders Place Their Bets

In other news, Director William J. Chase acquired 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were bought at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the acquisition, the director owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total value of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares in the company, valued at approximately $960,523.08. This represents a 3.27% decrease in their position. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by company insiders.

Intellia Therapeutics Trading Down 1.1%

Shares of NASDAQ:NTLA opened at $25.60 on Monday. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $28.25. The company’s 50 day moving average is $16.82 and its 200 day moving average is $12.13. The company has a market cap of $2.75 billion, a PE ratio of -5.46 and a beta of 2.37.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. The company had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. Intellia Therapeutics’s quarterly revenue was up 104.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.52) EPS. Equities research analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on NTLA shares. Chardan Capital lowered their price objective on shares of Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Guggenheim reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, August 13th. Royal Bank Of Canada lowered their price objective on shares of Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Saturday. Finally, Citizens Jmp raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $33.00 price objective for the company in a research note on Monday, October 6th. Thirteen analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $28.47.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.